CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Vincerx Pharma, Inc. - VINC CFD

    0.94
    13.25%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Vincerx Pharma Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.83
    Open* 0.85
    1-Year Change* -12.37%
    Day's Range* 0.85 - 0.94
    52 wk Range 0.61-1.95
    Average Volume (10 days) 2.69M
    Average Volume (3 months) 10.31M
    Market Cap 24.59M
    P/E Ratio -100.00K
    Shares Outstanding 21.38M
    Revenue N/A
    EPS -2.30
    Dividend (Yield %) N/A
    Beta 0.10
    Next Earnings Date Mar 26, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 22, 2024 0.83 -0.02 -2.35% 0.85 0.85 0.80
    Apr 19, 2024 0.82 -0.03 -3.53% 0.85 0.88 0.80
    Apr 18, 2024 0.87 -0.04 -4.40% 0.91 0.91 0.83
    Apr 17, 2024 0.91 0.01 1.11% 0.90 0.96 0.88
    Apr 16, 2024 0.91 0.07 8.33% 0.84 0.94 0.82
    Apr 15, 2024 0.83 -0.09 -9.78% 0.92 0.95 0.81
    Apr 12, 2024 0.94 -0.04 -4.08% 0.98 0.98 0.93
    Apr 11, 2024 0.97 -0.01 -1.02% 0.98 1.01 0.89
    Apr 10, 2024 0.97 -0.02 -2.02% 0.99 1.13 0.94
    Apr 9, 2024 1.04 -0.57 -35.40% 1.61 1.62 1.02
    Apr 8, 2024 4.74 -0.70 -12.87% 5.44 5.54 4.65
    Apr 5, 2024 5.54 -0.24 -4.15% 5.78 6.00 4.84
    Apr 4, 2024 5.89 -0.77 -11.56% 6.66 6.66 5.84
    Apr 3, 2024 6.55 0.15 2.34% 6.40 6.72 5.98
    Apr 2, 2024 6.25 0.52 9.08% 5.73 6.38 5.53
    Apr 1, 2024 5.80 0.94 19.34% 4.86 5.90 4.55
    Mar 28, 2024 4.98 -0.90 -15.31% 5.88 5.93 4.92
    Mar 27, 2024 5.93 0.80 15.59% 5.13 6.04 4.98
    Mar 26, 2024 5.08 0.11 2.21% 4.97 5.40 4.86
    Mar 25, 2024 4.89 -0.14 -2.78% 5.03 5.13 4.65

    Vincerx Pharma, Inc. Events

    Time (UTC) Country Event
    Thursday, May 9, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q1 2024 Vincerx Pharma Inc Earnings Release
    Q1 2024 Vincerx Pharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, May 23, 2024

    Time (UTC)

    17:00

    Country

    US

    Event

    Vincerx Pharma Inc Annual Shareholders Meeting
    Vincerx Pharma Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Monday, August 5, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q2 2024 Vincerx Pharma Inc Earnings Release
    Q2 2024 Vincerx Pharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2020 2019
    Total revenue 0 0 0 0 0
    Total Operating Expense 73.574 62.656 10.714 0.173 0.00145
    Other Operating Expenses, Total 0.173 0.00145
    Operating Income -73.574 -62.656 -10.714 -0.173 -0.00145
    Net Income Before Taxes -65.367 -39.306 -16.62 -0.11873 -0.00145
    Net Income After Taxes -65.367 -39.306 -16.62 -0.11954 -0.00145
    Net Income Before Extra. Items -65.367 -39.306 -16.62 -0.11954 -0.00145
    Net Income -65.367 -39.306 -16.62 -0.11954 -0.00145
    Income Available to Common Excl. Extra. Items -65.367 -39.306 -16.62 -0.11954 -0.00145
    Income Available to Common Incl. Extra. Items -65.367 -39.306 -16.62 -0.11954 -0.00145
    Diluted Net Income -65.367 -39.306 -16.62 -0.11954 -0.00145
    Diluted Weighted Average Shares 21.029 17.176 5.252 1.70157 6.25
    Diluted EPS Excluding Extraordinary Items -3.10842 -2.28843 -3.16451 -0.07025 -0.00023
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -2.99101 -2.28843 -3.16451 -0.07025 -0.00023
    Interest Income (Expense), Net Non-Operating 6.967 23.358 -5.906 0.05427
    Selling/General/Admin. Expenses, Total 18.953 22.575 3.598
    Research & Development 52.152 40.081 7.116
    Other, Net 1.24 -0.008
    Unusual Expense (Income) 2.469
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 11.66 15.099 15.423 16.901 19.623
    Selling/General/Admin. Expenses, Total 3.787 4.512 4.05 4.525 4.722
    Research & Development 7.873 10.587 11.373 11.066 13.742
    Operating Income -11.66 -15.099 -15.423 -16.901 -19.623
    Interest Income (Expense), Net Non-Operating 0.209 0.484 0.429 0.125 1.202
    Net Income Before Taxes -11.151 -14.341 -13.643 -16.879 -18.421
    Net Income After Taxes -11.151 -14.341 -13.643 -16.879 -18.421
    Net Income Before Extra. Items -11.151 -14.341 -13.643 -16.879 -18.421
    Net Income -11.151 -14.341 -13.643 -16.879 -18.421
    Income Available to Common Excl. Extra. Items -11.151 -14.341 -13.643 -16.879 -18.421
    Income Available to Common Incl. Extra. Items -11.151 -14.341 -13.643 -16.879 -18.421
    Diluted Net Income -11.151 -14.341 -13.643 -16.879 -18.421
    Diluted Weighted Average Shares 21.274 21.188 21.14 21.083 20.995
    Diluted EPS Excluding Extraordinary Items -0.52416 -0.67685 -0.64536 -0.8006 -0.8774
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.52416 -0.67685 -0.64536 -0.73846 -0.8222
    Other, Net 0.3 0.274 1.351 -0.103 0
    Unusual Expense (Income) 0 0 1.31 1.159
    • Annual
    • Quarterly
    2022 2021 2020 2020 2019
    Total Current Assets 55.964 111.841 63.11 0.79104 0.025
    Cash and Short Term Investments 52.459 111.459 61.792 0.68471 0.025
    Cash 0.68471 0.025
    Total Assets 59.286 117.676 63.192 66.483 0.025
    Other Long Term Assets, Total 0.081 1.653 0.082 0
    Total Current Liabilities 9.156 13.919 37.813 0.11626 0.00145
    Payable/Accrued 4.715 0.11545 0.00145
    Accrued Expenses 5.947 0.738 0
    Notes Payable/Short Term Debt 0 0 0.014 0 0
    Total Liabilities 11.618 17.355 37.813 3.41358 0.00145
    Total Long Term Debt 0 0 0 0 0
    Total Equity 47.668 100.321 25.379 63.0694 0.02355
    Common Stock 0.002 0.002 0.001 58.0696 0.00014
    Additional Paid-In Capital 169.03 156.311 42.043 5.12076 0.02486
    Retained Earnings (Accumulated Deficit) -121.338 -55.971 -16.665 -0.12099 -0.00145
    Total Liabilities & Shareholders’ Equity 59.286 117.676 63.192 66.483 0.025
    Total Common Shares Outstanding 21.2429 21.0576 13.9844 8.20471 6.25
    Prepaid Expenses 1.694 0.182 1.104 0.10633
    Long Term Investments 65.6919
    Other Current Liabilities, Total 0.144 6.447 37.308 0.00081
    Other Liabilities, Total 2.462 3.436 3.29732
    Cash & Equivalents 11.663 111.459 61.792
    Other Current Assets, Total 0.439 0.2 0.214
    Accounts Payable 3.065 2.019 0.491
    Other Equity, Total -0.026 -0.021 0
    Property/Plant/Equipment, Total - Net 3.241 4.182
    Short Term Investments 40.796
    Total Receivables, Net 1.372
    Property/Plant/Equipment, Total - Gross 3.32
    Accumulated Depreciation, Total -0.079
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 22.818 31.813 44.007 55.964 67.255
    Cash and Short Term Investments 20.802 27.359 39.768 52.459 65.975
    Cash & Equivalents 15.078 6.679 4.489 11.663 45.804
    Prepaid Expenses 0.322 0.636 0.807 0.134 0.47
    Other Current Assets, Total 0.641 2.434 3.432 3.371 0.81
    Total Assets 26.276 35.275 47.448 59.286 72.376
    Property/Plant/Equipment, Total - Net 2.584 2.838 3.087 3.241 3.479
    Other Long Term Assets, Total 0.874 0.624 0.354 0.081 1.642
    Total Current Liabilities 8.846 9.157 10.712 9.156 9.95
    Accounts Payable 3.062 3.533 6.173 3.065 4.393
    Payable/Accrued 4.526 4.288 3.355 4.445
    Accrued Expenses 1.126 1.092 1.058 5.947 0.999
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.132 0.244 0.126 0.144 0.113
    Total Liabilities 10.535 11.139 12.982 11.618 12.669
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 1.689 1.982 2.27 2.462 2.719
    Total Equity 15.741 24.136 34.466 47.668 59.707
    Common Stock 0.002 0.002 0.002 0.002 0.002
    Additional Paid-In Capital 172.232 170.895 170.108 169.03 167.463
    Retained Earnings (Accumulated Deficit) -156.545 -146.83 -135.679 -121.338 -107.695
    Other Equity, Total 0.052 0.069 0.035 -0.026 -0.063
    Total Liabilities & Shareholders’ Equity 26.276 35.275 47.448 59.286 72.376
    Total Common Shares Outstanding 21.3806 21.3806 21.2458 21.2429 21.1898
    Short Term Investments 5.724 20.68 35.279 40.796 20.171
    Total Receivables, Net 1.053 1.384
    • Annual
    • Quarterly
    2022 2021 2020 2020 2019
    Net income/Starting Line -65.367 -39.306 -16.62 -0.11954 -0.00145
    Cash From Operating Activities -59.604 -33.402 -2.279 -0.16533 0
    Changes in Working Capital -1.02 5.609 -0.959 0.00848 0.00145
    Cash From Financing Activities 0.28 88.453 64.071 66.4627 0.025
    Financing Cash Flow Items 64.07 0.60279 0
    Issuance (Retirement) of Stock, Net 0.28 88.453 0.001 65.8599 0.025
    Net Change in Cash -99.831 49.772 61.792 0.65971 0.025
    Non-Cash Items 6.729 0.27 15.3 -0.05427
    Cash From Investing Activities -40.578 -5.258 -65.6377
    Other Investing Cash Flow Items, Total -40.578 -5 -65.6377
    Cash Taxes Paid 0
    Cash Interest Paid 0 0.025 0.025
    Issuance (Retirement) of Debt, Net 0 0
    Cash From Operating Activities 0.054 0.025
    Capital Expenditures 0 -0.258
    Foreign Exchange Effects 0.071 -0.021
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -14.341 -65.367 -51.724 -34.845 -16.424
    Cash From Operating Activities -13.092 -59.604 -45.787 -30.915 -15.028
    Non-Cash Items 0.861 6.729 5.177 2.642 0.263
    Cash Taxes Paid 0
    Cash Interest Paid 0 0 0 0 0
    Changes in Working Capital 0.375 -1.02 0.72 1.261 1.119
    Cash From Investing Activities 5.885 -40.578 -20.195 0 0
    Other Investing Cash Flow Items, Total 5.885 -40.578 -20.195 0 0
    Net Change in Cash -7.174 -99.831 -65.696 -30.644 -15.011
    Capital Expenditures 0 0 0
    Cash From Financing Activities 0.003 0.28 0.242 0.242
    Issuance (Retirement) of Stock, Net 0.003 0.28 0.242 0.242
    Issuance (Retirement) of Debt, Net
    Cash From Operating Activities 0.013 0.054 0.04 0.027 0.014
    Foreign Exchange Effects 0.03 0.071 0.044 0.029 0.017

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Vincerx Pharma, Inc. Company profile

    About Vincerx Pharma Inc

    Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and oncology knowledge to advance new therapies for the treatment of cancer. The Company’s small molecule drug program includes VIP152, which is a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are ADC compounds addressing known and novel oncology targets. The Company’s bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Vincerx Pharma Inc revenues was not reported. Net loss totaled to $32.8M. Results are not comparable due to year end change.

    Industry: Bio Therapeutic Drugs

    260 Sheridan Avenue
    Suite 400
    PALO ALTO
    CALIFORNIA 94306
    US

    Income Statement

    • Annual
    • Quarterly

    News

    We’re partnering with Newsquawk

    Filter out the noise and focus on the news that matters.

    08:32, 23 April 2024

    US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft

    The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.

    15:56, 22 April 2024

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    People also watch

    ETH/USD

    3,241.46 Price
    +1.530% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    XRP/USD

    0.56 Price
    -1.910% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    US100

    17,495.20 Price
    +1.640% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    BTC/USD

    66,832.35 Price
    +0.430% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading